去甲氧柔红霉素联合方案治疗复发儿童急性淋巴细胞白血病  

Idarubicin combined regimen in treatment of 37 cases of relapsed childhood acute lymphoblastic leukemia

作　　者：丁婧[1] 王叨[1] 李白[1] 刘玉峰[1] 

机构地区：[1]郑州大学第一附属医院,450052

出　　处：《中国实用医刊》2016年第10期65-67,共3页Chinese Journal of Practical Medicine

摘　　要：目的：探讨应用去甲氧柔红霉素（IDA）为主的联合化疗方案治疗急性淋巴细胞白血病（ALL）复发患儿的疗效及其不良反应。方法37例急性淋巴细胞白血病复发患儿均采用 VILP（长春新碱、去甲氧柔红霉素、左旋门冬酰胺酶、泼尼松）诱导缓解方案治疗。完全缓解（CR）后行巩固治疗，然后再用 VILP 早期强化治疗。结果37例患儿均获完全缓解（100％），化疗完全结束15例（40.5％），其中无病生存期（ESF）≥6个月6例，≥3个月6例，≥1个月3例；14例（37.8％）仍继续化疗；8例（21.6％）死亡。接受造血干细胞移植7例（18.9％），其中无病生存患儿4例，死亡3例。结论以去甲氧柔红霉素为主的联合方案是治疗儿童 ALL 复发患儿有效的方法，对复发患儿作为一线药物其远期疗效会更好。Objective To investigate the efficacy and side effects of idarubicin（IDA）based combination chemotherapy regimen for relapsed childhood with acute lymphoblastic leukemia（ ALL）. Methods Thirty-seven cases of relapsed childhood acute lymphoblastic leukemia adopted VILP（vincris-tine,idarubicin,L-asparaginase,prednisone）induced by solution treatment. For consolidating treatment after complete remission（CR）,and then used VILP as early intensive treatment. Results Thirty-seven cases（100% ）all received CR. Fifteen cases（40. 5% ）were completely over chemotherapy,which achieved to event free survival（EFS）≥ 6 months in 6 cases,≥3 months in 6 cases,≥1 month in 3 ca-ses;14 cases（37. 8% ）continued to chemotherapy;8 cases（21. 6% ）died. There were 7 cases（18. 9% ）accepted hematopoietic stem cell transplantation,among which 4 cases of them were in EFS,and 3 cases died. Conclusions Idarubicin is an effective method which is given priority to combination chem-otherapy regimen for relapsed childhood with ALL,and as first-line drugs for children with recurrent the long-term curative effect will be better.

关 键 词：去甲氧柔红霉素 急性淋巴细胞白血病 复发 无病生存 

分 类 号：R733.71[医药卫生—肿瘤]